- 1 Antibody response to SARS-CoV-2 infection over six months among Nicaraguan
- 2 outpatients.
- 3 Fredman González^{1†}, Omar Zepeda^{1†}, Christian Toval-Ruiz¹, Armando Matute¹, Hernan
- 4 Vanegas¹, Nancy Munguia¹, Edwing Centeno¹, Yaoska Reyes¹, Lennart Svensson², Johan
- 5 Nordgren², Aravinda M. de Silva³, Sylvia Becker-Dreps⁴, Lakshmanane Premkumar³, Filemón
- 6 Bucardo¹.
- ¹The Faculty of Medical Science, National Autonomous University of Nicaragua, León (UNAN-
- 8 León). ²Division of Molecular Virology, Department of Clinical and Experimental Medicine,
- 9 Linköping University, Linköping, Sweden. ³Department of Microbiology and Immunology,
- 10 University of North Carolina School of Medicine, Chapel Hill NC 27599, USA. ⁴Departments of
- 11 Family Medicine and Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill,
- 12 North Carolina, USA.
- [†] Equally contributions.
- 14 Corresponding author:
- 15 Filemon Bucardo.
- Department of Microbiology, Faculty of Medical Science
- 17 Campus Medico, 2nd floor
- 18 León, Nicaragua.
- 19 Email. fili_bucardo@hotmail.com
- 20 Keywords: Outpatients, RBD antigen, hematological and inflammatory markers.

Running title: Prolonged immune response to SARS-CoV-2 in outpatients.

ABSTRACT

1

2

21

3 New information is emerging about SARS-CoV-2 epidemiology and immunity, but little of this 4 information comes from low- and middle-income countries or from patients receiving care in the 5 outpatient setting. The current study investigated the SARS-CoV-2 infection status and antibody 6 responses in 157 patients seeking care for a respiratory disease suggestive of COVID-19 in private healthcare clinics during the first wave (June-October 2020) of infections in Nicaragua. 7 We examined nasal swabs for the presence of viral RNA via RT-PCR and longitudinally 8 9 collected sera for the changes in SARS-CoV-2 Spike antibody levels over six months. Among 10 patients with confirmed SARS-CoV-2 infections, we evaluated if clinical symptoms were associated with age, hematological parameters and co-morbidities. The combination of PCR and 11 12 paired serology identified 60 (38%) of the 157 outpatients as acute COVID-19. While both PCR and serology identified the majority (n = 38, 64%) of the acute infections, a notable number of 13 14 outpatients were identified by RT-qPCR (n = 13, 22%) or by serology (n = 9, 14%) only. During 15 the longitudinal study, we identified 6 new infections by serology among the 97 non-COVID-19 subjects. In conclusion, this study report that more than one third of the outpatients seeking care 16 17 for acute respiratory disease during the first epidemic wave of SARS-CoV-2 in Nicaragua had an acute mild COVID-19 infection that correlate with prolonged humoral response. This immune 18 response to the RBD antigen, more likely IgG dependent, significantly increased between the 19 acute to convalescent and decay in the late convalescent but still remained seropositive. 20

INTRODUCTION

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

Coronavirus disease (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) discovered in Wuhan, China in mid-December 2019 [1]. The disease is characterized by fever, dry cough, shortness of breath, sore throat, myalgia, fatigue and headache, often accompanied by lymphopenia, prolonged prothrombin and elevated lactate dehydrogenase [2, 3]. Older people, and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness [4]. In contrast, young and healthy people infected with SARS-CoV-2 typically experience mild to moderate respiratory illness and recover without requiring special treatment [5, 6]. Despite the rapidly growing body of knowledge on SARS-CoV-2 infections, more information is needed to better understand disease susceptibility and immunity. For example, more information is needed on whether severe, moderate, mild or asymptomatic SARS-CoV-2 infection elicit persistent immune memory that is protective. The persistence of immunity has important implications for individual protection after infection and community immunity. Another priority for is understanding whether host genetic factors contribute to disease susceptibility or severity. In several studies, blood group O has been associated with lower risk of COVID-19, while non-O blood types are associated with increased risk [7]. The coronavirus (CoV) virion consists of a nucleocapsid core surrounded by an envelope containing three membrane proteins, spike (S), membrane (M) and envelope (E) that are common to all members of the genus [8]. SARS-CoV-2 is a β-CoV, a subgroup that includes SARS-CoV-1, MERS-CoV and the two common-cold human CoVs, OC43 and HKU-1 [9]. The Receptor Binding Domain (RBD) of the spike protein (S) is highly immunogenic and elicit antibodies that are strongly correlated with SARS-CoV-2 neutralization [10-12]. In longitudinal

analyses SARS-CoV-2 IgA and IgM antibodies have been shown to decay rapidly, while IgG antibodies remained relatively stable up to 6 months or longer in serum and saliva [13-15]. The median time to seroconversion has been estimated to be between 9 and 12 days post-symptoms onset (PSO) for IgM, IgA and IgG antibodies against RBD [16, 17]. In contrast, the median times for IgM and IgA seroreversion appear to be around 49 and 71 days PSO, respectively [16].

Few SARS-CoV-2 longitudinal studies have been conducted in patients seeking care in the outpatients setting and in South American populations to estimate the burden of disease and to monitor the durability of immunity. Here we report on the burden of SARS-CoV-2 infections among patients with respiratory symptoms presenting to outpatient clinics during the first wave of the pandemic in Nicaragua. We also followed this cohort of patients for 6 months to assess the durability of SARS-CoV-2-specific antibodies among patients with an initial presentation of mild disease that resolved with no complications in the majority of the patients. Our results are applicable to estimating the burden of COVID-19 disease in Nicaragua and understanding the durability of antibodies among patients with mild to moderate disease.

RESULTS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

Laboratory diagnosis of acute COVID-19 by RT-qPCR and paired serology. A total of 51 of the 157 outpatients had SARS-CoV-2 RNA detected in NP swabs collected during the acute phase; the Ct median was 24.6 (IQR, 20.3 - 32.0) (Table. 1). When paired acute and convalescent blood samples were tested for SARS-CoV-2 RBD specific antibody, we observed 47/157 (30%) of patients seroconverted confirming acute SARS-CoV-2 infection (Table. 1). In total 60 of 157 (38%) patients tested positive by PCR or paired serology (Fig. 1A). Of the 60 subjects diagnosed with acute SARS-CoV-2 infection, 38 (63%) were identified by both assays (Fig. 1B), 13 (22%) by RT-qPCR only (Fig 1C) and 9 (15%) by serology only (Fig.1D). Retesting of the NP samples from subjects classified as "serology only" with a secondary, more sensitive, RT-qPCR assay showed amplification in 7 of 9, but Ct values were all >33 indicating low viral load. Of the 13 acute cases identified by PCR only, 5 subjects already had developed antibody in the acute specimen, with no evidence for seroconversion in those that provided a convalescent serum, 3 subjects did not develop detectable antibody in acute or convalescent specimens. The infection status of 5 subjects could not be established by serology as convalescent blood samples were not available (Fig. 1C). Of the 97 outpatients who tested negative for acute SARS-CoV-2 infection, 16 had RBD Specific-Ig antibody but not IgM in the acute specimen (collected <5 days PSO), which is indicative of a past infection not linked to the current illness (Fig. 1E). In summary, in the 157 patients evaluated, we observed 60 SARS-CoV-2 incident infections (38%) and 16 (10%) past infections. Temporal patterns of reactivity to the SARS-RBD antigen. Subjects who tested seropositive in either acute or convalescent specimens were invited to provide a second late convalescent serum sample (>120 days PSO) to measure the durability of SARS-CoV-2 RBD binding

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

antibodies. In total 53 subjects consented to participate, including 39 diagnosed with acute COVID-19 and 14 non-COVID-19 cases. The longitudinal analysis of RBD reactivity showed 3 different reactivity patterns. The first pattern observed in 29 subjects showed an increase in signal from acute to the first convalescent specimen and a decrease in signal from early and late convalescent specimen, likely due in part to the decline of IgA and IgM antibodies (Fig.2A and Fig 2E). The second pattern observed in 16 subjects showed a similar increase between the acute and the early convalescent but the signal remained high or even increased between the early and the late-convalescent specimens (Fig. 2B). The third pattern observed in 9 subjects showed either seroconversions (n = 5) or boost (n = 3) in antibody levels between the early and the late convalescent specimens indicative of incident infections and, possibly, re-exposure to antigen (Fig. 2C). Pan-Ig reactivity to the SARS-CoV-2 RBD antigen lasted for at least 6-month postacute infection in the outpatients from this cohort (Fig. 2D) and IgG response was higher and more prolonged than IgM and IgA responses (Fig. 2E). Clinical and Epidemiological fingerprint of COVID-19 in outpatients from León, Nicaragua. Among several parameters examined in outpatient with acute respiratory disease, the following epidemiological characteristics were all associated (p < 0.05) with acute COVID-19 (n = 60) as compared to a non-COVID-19 illness (n = 97); age between 40 and 60 years (OR = 2.1), less frequent hand washing (≤ 5 times/day; OR = 2.8) and contact with a pet (OR = 2.8) (Table. 2). Among the clinical symptoms, fever (OR = 4.2), loss of taste (OR = 2.4), smell (OR = 3.0)and appetite (OR = 2.1) were associated with acute COVID-19 (Table. 3). The frequency of patients with ≥2 comorbidities was higher in acute-COVID-19 than in non-COVID-19 patients (28% vs 19%) and the most common was diabetes (18% vs 9%). After examination of several laboratory parameters, lower white cells count, presence of immature granulocytes, lower

relative percent of eosinophils, higher INR, CRP-positivity and lower erythrocyte sedimentation rate were all associated with acute COVID-19 (Table. 4). Interestingly, while most hematologic parameters in convalescent blood normalized, participants with an acute COVID-19 diagnosis had persistently lower hemoglobin, red blood cell counts and hematocrit. Patients with acute COVID-19 were more likely to be treated with, ivermectin, azitromycin, aspirin and Vitamin C (Supplement). During the convalescent visit, 4 (2.5%) of 157 reported hospitalizations for their illness and 2 (1.3%) fatalities were confirmed; both of them had a diagnosis of acute COVID-19. There was an association between the frequency of outpatient with diagnosis of acute COVID-19 from the current study and confirmed cases from Nicaragua, mainly derived from hospitalized patients, reported in the Johns Hopkins University website [18] (Fig. 3).

DISCUSION

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

The current study contributes to our understanding of the humoral response to SARS-CoV-2 over 6 months in outpatients in Nicaragua a country with limited epidemiological and immunological data during the COVID-19 pandemic. This study also extends previous knowledge on clinical, epidemiological, laboratory diagnosis and treatment associated with acute SARS-CoV-2 infection in outpatients. Molecular and serological testing confirmed that more than one third of the outpatients seeking care for acute respiratory disease during the first epidemic wave of SARS-CoV-2 in Nicaragua had an acute COVID-19 infection (Table 1). Other infectious etiologies with a similar clinical and epidemiological profile that may have been co-circulating in this setting at the same time frame (June - October 2020), such as influenza or pneumococcal, remain to be investigated. Acute respiratory infections typically peak in incidence between July and October in Nicaragua [19]. Initial serologic analysis to explore antibody response to the RBD antigen showed 3 categories, the first includes subjects with naïve acute serum but highly reactive convalescent serum to the RBD antigen (Fig. 1B), the second were subjects with acute and convalescent serum highly or mildly reactive to the RBD antigen, indicative of prior infection if the serum was collected < 5 days PSO (Fig. 1E) and the third includes subjects that do not experience seroconversion to the RBD antigen despite RNA detection in NP by RT-qPCR (Fig. 1C). The reactivity to the RBD antigen observed in most of the acute outpatients with COVID-19 indicate activation of the humoral response and is suggestive of the development of neutralizing antibodies with the capacity to block SARS-COV-2 spike protein interaction with its cognate receptor ACE-2 as previously reported [17, 20]. The presence of viral RNA without serological response suggests

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

false-positive PCR or atypical antibody responses, which have been reported in some patients [17, 21]. Genomic studies have shown a continuous emergence of novel variants in several populations, although there is little information on the presence of these or other variants in Central American populations [22, 23]. It was also interesting to observe RT-qPCR negative individuals with strong reactivity to the RBD antigen in convalescent serum suggestive of falsenegative RT-qPCR test (Fig. 1D). Re-examination with an alternative RT-qPCR that used more sensitive primers and probes to the E region [24] than the Charité system [25] showed RNA amplification in 7 of those 9 subjects, confirming that these were indeed false negatives. Our results demonstrate the value of using both RT-qPCR and paired serology for laboratory confirmation of acute COVID-19 cases. We also analyzed a subset of acute COVID-19 cases to understand the long-term dynamics of antibody responses. We observed three patterns of changes in antibody levels over a 6 month follow up period. In the first pattern, reactivity to the RBD antigen significantly increased between the acute to convalescent, thereafter decreased in the late convalescence, but remained seropositive up to 6 months (Figs. 2A). In the second pattern, the reactivity did not decay and remained high between convalescent and late convalescent sera, indicative of strong immune response over 6 months (Fig. 2B). The third pattern was characterized by incident infections and boost in the reactivity to RBD between convalescent and late convalescent serum. The boost in Ab levels between convalescence and late convalescence may indicate a secondary subclinical infection, possibly by SARS-CoV-2 variants. The clinical symptoms and laboratory profiles of this Nicaraguan outpatient cohort follows the trend observed in hospitalized patients from several other studies [27, 28]. This profile includes loss of taste, smell and appetite, age 40 to 60 years, contact with pets, reduced hand washing,

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

lower leukocytes counts, lower eosinophils, increased INR and increased erythrocyte sedimentation rate. As compared with non-COVID-19 patients, C-reactive protein (CRP) test was more likely to be positive in COVID-19 outpatients (42% vs 48%, p < 0.05), suggesting that CRP positivity is common in patients mild COVID-19 disease as observed in severe cases with excessive inflammation [29]. In previous studies, the degree of lymphocytes count gives a hint for disease prognosis and is found to be positively correlated with disease severity [27]. For instance, preliminary studies from Wuhan reported lymphopenia in 80% of the critical patients and 25% in patients with mild COVID-19 infection [30, 31]. Given the significantly lower leucocytes counts observed in COVID-19 patients in this study, is likely that they also experienced lower lymphocytes counts, but with similar differential white blood cell proportions (35.5% vs 34.6%) as compare with non-COVID-19 patient, which is in line with mild disease. It has previously been suggested that lower eosinophils counts is associated with acute respiratory deterioration during SARS-CoV-2 [32], the current study further show that lower eosinophils counts is also associated with non-severe disease and might be considered a marker of infection in general. A similar multidrug therapy (ivermectin, azithromycin and aspirin) to the used in the current study have shown to improve recovery and prevent risk of hospitalization and death among ambulatory COVID-19 cases in Mexico [33], but further effectiveness studies will be needed to reach any conclusion. The correlation between the COVID-19 status and the distribution of ABO, Lewis and Secretors phenotypes was explored, but the lower frequency of the non-O blood, LeA and Se-phenotypes in this population required a higher sample size to establish a reliable conclusion. In conclusion, this study report that more than one third of the outpatients seeking care for acute respiratory disease during the first epidemic wave of SARS-CoV-2 in Nicaragua had an acute

- 1 mild COVID-19 infection that correlate with prolonged humoral response. This immune
- 2 response to the RBD antigen, more likely IgG dependent, significantly increased between the
- 3 acute to convalescent and decay in the late convalescent but still remained seropositive.

MATERIAL AND METHODS.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

Study subjects. A total of 157 patients, with a median of 43 years of age (IQR, 32 - 59), seeking care for respiratory disease suggestive of COVID-19 in private healthcare clinics were prospectively enrolled between June to October 2020 in Leon, Nicaragua. Following the clinician's consultation each patient was asked by phone to participate in the study. Interested patients were visited in their household by the study team within 17 days PSO to obtain informed consent and collect clinical and demographic data in a questionnaire. Nasopharyngeal swabs and blood samples were collected for RT-qPCR and Pan-immunoglobulin (IgM, IgG and IgA) screening, respectively. Patients were also asked to provide a second blood sample during convalescent phase, 20 to 60 days PSO, and a third blood sample (late-convalescent) between 120 – 180 days PSO. This study was approved by the ethical committee for biomedical research from UNAN-León, 2020 and amended in September 2020 on May (FWA00004523/IRB00003342). All patients signed an inform consent and all methods applied in accordance with guidelines and regulations, such as, good clinical and laboratory practices. Samples collection. Nasopharyngeal samples (NP) were collected following recommendations by the World Health Organization (WHO) for the rational use of personal protective equipment (PPE) in health care and home care settings [34]. Assays for examination hematological parameters and markers of inflammation. The relative percentages of neutrophil, lymphocyte, eosinophil, monocyte and basophil were manually examined by using Wright staining. Qualitative and semi-quantitative C reactive protein (CRP), partial thromboplastin time (PTT) and prothrombin time (PT) were determined with the HumaTex CRP, Hemostat aPTT-EL and Hemostat Thromboplastin-SI latex agglutination kits, respectively (Human, Wiesbaden Germany). ABO blood groups were

1 determined by haemagglutination (Cypress Diagnostics, Hulshout, Belgium). Lewis A (LeA) 2 Lewis B (LeB) and H (secretor) antigens were detect using an in-house saliva-based ELISA [35]. 3 RT-qPCR for SARS-CoV-2 screening. Viral RNA extraction was performed from 140µl of the 4 solution containing the nasopharyngeal (NP) swab by using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany), according to manufacturer's instructions. Purified viral RNA was 5 6 analyzed by RT-qPCR for SARS-CoV-2 screening by using the Sarbeco-E primers and probes described in the Charité assay [25]. The primers and probes for the RdRp gene described in the 7 Charité assay were not considered based in a previous report showing low sensitivity [36]. RT-8 9 qPCR was performed with the AgPath-ID OneStep RT-PCR Kit (Thermo Fisher Scientific, 10 Waltham, MA) using a Light Cycler®96 (Roche, Mannheim, Germany). A sample was considered positive if the cycle threshold (Ct) value was ≤ 36. NP samples from patients 11 12 diagnosed by serology only were re-examined with primers and probes described by Smyrlaki and coworkers, $Ct \le 36$ [24]. 13 14 **In-house RBD ELISA.** The protein expression and purification of the recombinant SARS-CoV-15 2 RBD antigen used were previously described by Premkumar and coworkers [17]. The sensitivity and specificity of this assay to detect SARS-CoV-2 antibodies have been found to be 16 17 98% and 100% at 9 days PSO, respectively [17]. In brief, anti-RBD specific immunoglobulins (Ig) and IgM antibodies (ab) were determined by ELISA using heat inactivated serum at 56°C 18 for 30 minutes. The 96-well high-binding microtiter plate (Greiner bio one cat # 655061) was 19 20 coated with 50 µl of the RBD antigen at 4µg/ml in Tris Buffered Saline (TBS) pH 7.4 for 1 hr at 37°C. Plates were blocked with 100 µl of blocking solution (3% non-fat milk (Pinito) in TBS 21 22 containing 0.05% Tween 20) for 1 hr at 37°C and 50 µl of serum at 1:40 in blocking buffer was added and incubated for 1 hr at 37°C. After washing (TBS-tween-tween 0.2% v/v), 50 µl of goat 23

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

anti-human alkaline phosphatase conjugated antibody mixture at 1:2500 dilution was added for 1 hr at 37°C 1. The mixture contains anti-IgG (Sigma Cat # A9544), anti-IgA (Ab cam Cat # AB97212), and anti-IgM (Sigma Cat # A3437) antibodies conjugated with alkaline phosphatase. After washing, 50 µl P-Nitrophenyl phosphate substrate (SIGMA FAST, Cat No N2770) was added to the wells and the optical density (OD) was measured after 10 min at 405nm by using a plate reader (Biotek Epoh). Acute serum with OD readings of ≥0.300 in the Pan-immunoglobulin RBD assay (Pan-Ig-RBD) were defined as seropositive. OD readings of ≥ 0.300 in acute samples collected ≤5days PSO were indicative of prior infection if Pan-Ig was positive but IgM-negative. In seropositive patients, a recent infection or seroconversion was defined as the ratio between the OD-convalescent/OD-acute ≥2. All subjects seropositive in acute and convalescent serum were asked to provide a third sample to investigate prolonged humoral response. All acute, convalescent and late convalescent serum samples were analyzed for IgG, IgA and IgM separately using isotype specific goat anti-human antibody by following the same procedure used for Pan-Ig. Statistics. Patients RT-qPCR-positive and/or seroconverted were defined as acute COVID-19 and RT-qPCR-negative with non-seroconversion was defined as non-COVID-19. Arithmetic mean with standard deviation (±SD) was used to compare continuous variables. Frequency and percentages were used to compare categorical variables. The differences between two groups of continuous variables was tested by using independent t-test. A regression univariate model was applied to explore risk factors associated with acute COVID-19, only categorical variables were included in the model. Odds Ratio (OR) was calculated to determine the degree of association at 95% confident interval (95%, CI), the association was significant if α was <0.05, all statistical

- 1 tests were two-sided. All statistical analysis was performed in Statistical Package for the Social
- 2 Sciences (SPSS version 21).
- 3 REFERENCES.
- 4 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019.
- 5 The New England journal of medicine **2020**; 382:727-33.
- 6 2. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with
- 7 2019 novel coronavirus and influenza virus in Wuhan, China. Journal of medical virology 2020; 92:1549-
- 8 55
- 9 3. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
- 10 Coronavirus-Infected Pneumonia in Wuhan, China. Jama 2020; 323:1061-9.
- 4. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically
- ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395:1763-70.
- 13 5. Felsenstein S, Hedrich CM. SARS-CoV-2 infections in children and young people. Clinical immunology
- **2020**; 220:108588.
- 15 6. Ballow M, Haga CL. Why do some people develop serious COVID-19 disease after infection, while
- others only exhibit mild symptoms? The journal of allergy and clinical immunology in practice 2021.
- 17 7. Pendu JL, Breiman A, Rocher J, Dion M, Ruvoen-Clouet N. ABO Blood Types and COVID-19: Spurious,
- Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data. Viruses 2021; 13.
- 19 8. Tan YJ, Lim SG, Hong W. Characterization of viral proteins encoded by the SARS-coronavirus genome.
- 20 Antiviral research **2005**; 65:69-78.
- 21 9. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nature reviews Microbiology
- 22 **2019**; 17:181-92.
- 23 10. Meyer B, Drosten C, Muller MA. Serological assays for emerging coronaviruses: challenges and
- 24 pitfalls. Virus research **2014**; 194:175-83.
- 25 11. Che XY, Qiu LW, Liao ZY, et al. Antigenic cross-reactivity between severe acute respiratory syndrome-
- associated coronavirus and human coronaviruses 229E and OC43. The Journal of infectious diseases
- 27 **2005**; 191:2033-7.
- 12. Maache M, Komurian-Pradel F, Rajoharison A, et al. False-positive results in a recombinant severe
- 29 acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid-based western blot assay
- were rectified by the use of two subunits (S1 and S2) of spike for detection of antibody to SARS-CoV.
- 31 Clinical and vaccine immunology: CVI **2006**; 13:409-14.
- 32 13. Markmann AJ, Giallourou N, Bhowmik DR, et al. Sex disparities and neutralizing antibody durability
- 33 to SARS-CoV-2 infection in convalescent individuals, medRxiv: the preprint server for health sciences
- 34 **2021**.
- 35 14. Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike
- antigens in COVID-19 patients. Science immunology **2020**; 5.
- 37 15. Jiang XL, Wang GL, Zhao XN, et al. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19
- 38 patients three months after infection. Nature communications **2021**; 12:897.
- 39 16. Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the
- 40 receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Science immunology 2020;
- 41 5.

- 1 17. Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike
- 2 protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Science
- 3 immunology **2020**; 5.
- 4 18. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The
- 5 Lancet Infectious diseases 2020; 20:533-4.
- 6 19. Gordon A, Tsang TK, Cowling BJ, et al. Influenza Transmission Dynamics in Urban Households,
- 7 Managua, Nicaragua, 2012-2014. Emerging infectious diseases **2018**; 24:1882-8.
- 8 20. Feldman J, Bals J, Denis KS, et al. Naive human B cells can neutralize SARS-CoV-2 through recognition
- 9 of its receptor binding domain. bioRxiv: the preprint server for biology **2021**.
- 10 21. Ranzenigo M, Pastori C, Siracusano G, Pariani E, Uberti-Foppa C, Lopalco L. Virological and
- 11 Serological Discordant Profiles in COVID-19 Pneumonia: Two Atypical Clinical Cases. Frontiers in
- immunology **2020**; 11:580867.
- 13 22. Guan Q, Sadykov M, Mfarrej S, et al. A genetic barcode of SARS-CoV-2 for monitoring global
- 14 distribution of different clades during the COVID-19 pandemic. International journal of infectious
- diseases: IJID: official publication of the International Society for Infectious Diseases 2020; 100:216-23.
- 16 23. Hernandez-Huerta MT, Perez-Campos Mayoral L, Romero Diaz C, et al. Analysis of SARS-CoV-2
- mutations in Mexico, Belize, and isolated regions of Guatemala and its implication in the diagnosis.
- 18 Journal of medical virology **2021**; 93:2099-114.
- 19 24. Smyrlaki I, Ekman M, Lentini A, et al. Massive and rapid COVID-19 testing is feasible by extraction-
- free SARS-CoV-2 RT-PCR. Nature communications **2020**; 11:4812.
- 25. Corman VM, Eckerle I, Bleicker T, et al. Detection of a novel human coronavirus by real-time reverse-
- 22 transcription polymerase chain reaction. Euro surveillance: bulletin Europeen sur les maladies
- transmissibles = European communicable disease bulletin **2012**; 17.
- 24 26. Sherina N, Piralla A, Du L, et al. Persistence of SARS-CoV-2 specific B- and T-cell responses in
- convalescent COVID-19 patients 6-8 months after the infection. Med 2021.
- 26 27. Dhama K, Khan S, Tiwari R, et al. Coronavirus Disease 2019-COVID-19. Clinical microbiology reviews
- 27 **2020**; 33.
- 28. Wang W, Chen L, He Q, et al. Clinical characteristics of inpatients with coronavirus disease 2019
- 29 (COVID-19) in Sichuan province. BMC infectious diseases **2021**; 21:155.
- 30 29. Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiological research 2020;
- 31 69:379-88.
- 30. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2
- pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet
- 34 Respiratory medicine **2020**; 8:475-81.
- 35 31. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel
- 36 coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507-13.
- 37 32. Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and
- 38 coronavirus vaccination. The Journal of allergy and clinical immunology **2020**; 146:1-7.
- 39 33. Lima-Morales R, Mendez-Hernandez P, Flores YN, et al. Effectiveness of a multidrug therapy
- 40 consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization
- 41 and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious
- diseases: IJID: official publication of the International Society for Infectious Diseases **2021**.
- 43 34. WHO. Rational use of personal protective equipment for COVID-19 and considerations during severe
- shortages. Interin Guidance **2020**:32.
- 45 35. Nordgren J, Sharma S, Bucardo F, et al. Both Lewis and secretor status mediate susceptibility to
- 46 rotavirus infections in a rotavirus genotype-dependent manner. Clinical infectious diseases : an official
- 47 publication of the Infectious Diseases Society of America **2014**; 59:1567-73.

- 1 36. Vogels CBF, Brito AF, Wyllie AL, et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2
- 2 RT-qPCR primer-probe sets. Nature microbiology **2020**; 5:1299-305.

4

ACKNOWLEDGEMENTS.

1

9

10

13

- 2 Authors would like to thanks all outpatients in the current study for attending the fieldwork staff
- and for providing the clinical samples. We also appreciate the support from Dr. Fabian Padilla
- 4 for the identification of COVID-19 suspected patients. FG, OZ, and YR are supported by an
- 5 award from the NIH-Fogarty International Center [D43TW010923]. SBD and LP are supported
- 6 by awards from the National Institute of Allergy and Infectious Diseases [K24AI141744 and
- 7 1U01AI151788-01, respectively]. LP also receive support from the National Cancer Institute
- 8 [NCI U54 CA260543-01] FB, JN and LS received support from the Swedish Research Council.

ADDITIONAL INFORMATION

- 11 Competing Interests
- 12 The authors declare no competing interests.

AUTHORS CONTRIBUTION

1

10

11

2 All authors have reviewed and approved this manuscript. Personal contribution are as follows: 3 FG, OZ, EC and YR carried out the experiments and contribute with data analysis, CTR contribute with statistical analysis, AM carried out the clinical evaluation of the patients and 4 review the clinical data, HV and NM collected the clinical and epidemiological information, 5 6 collected the biological material and perform experiments, LS and JN contribute in the study 7 design and data interpretation, AMS and LP synthetize de reagents, contribute with the study 8 design and perform data and manuscript curation, SBD contribute with study design, statistical 9 analysis revision and participate in the manuscript preparation. FB contribute with study design,

perform data analysis, coordinate laboratory and field activities and wrote the manuscript.

Figures Legends.

1

- 2 Figure 1. Patterns of Pan-Immunoglobulins response to the receptor binding domain of SARS-
- 3 COV-2 in acute and convalescent serum from outpatients with acute COVID-19 diagnosed by
- 4 RT-PCR and/or Serology between June and October 2020 in Nicaragua. A: All acute COVID-19
- 5 (n = 60), B: Acute-COVID-19 by RT-qPCR and Serology (n = 38), C: Acute COVID-19 by RT- $\frac{1}{2}$
- 6 qPCR only (n = 13), D: Acute-COVID by Serology only (n = 9) and E: All non-acute COVID-
- 7 19 (n=97).

8

- 9 **Figure 2.** Reactivity to the SARS-CoV-2 RBD antigen over 6 months post symptoms onset in
- outpatients from Nicaragua. A: Subjects exposed to SARS-CoV-2 (n = 29), black dot represents
- acute COVID-19 and black square past infections. B: Subjects with non-decaying reactivity to
- the RBD antigen in late convalescent serum (n = 18). C: Subjects with either incident infection
- between convalescent and late serum (n = 6). D: correlation between Pan-Ig reactivity to the
- RBD and days PSO (n = 53). E: Correlation between Pan-Ig and isotypes reactivity to the RBD
- in late convalescent serum.
- 16 **Figure. 3.** Correlation between the frequency of outpatients with acute COVID-19 from the
- current study and the reported in the Johns Hopkins University website to track COVID-19 in
- real time which is according to the Ministry of Health from Nicaragua.

- 1 Table 1. Summary of the RT-qPCR and Pan-Ig serology performed to confirm acute COVID-19
- 2 in outpatients with acute respiratory disease in Leon, Nicaragua between June and October
- 3 2021.

Assay	Acute SARS-0	CoV-2 infection	Serology-positive on acute sample	
	Positive	Negative	Positive	Total
RT-qPCR testing	51	106	-	157
Serology	47 ª	68	21	136 ^b
Final COVID-19 diagnosis				
Acute COVID-19	60 (38.0%)	13 (22%) positi 5 conv serolog 3 serol sample 5 acute 9 (15%) positiv	ogy negative in acute and conves. Esample with positive serology be by serology only. The desitive in re-testing with n	alescent
non-COVID-19	97 (62%)	65 (67%) negative by both assays 5 of these seroconverted between visits 2 and 3 16 (16%) PCR negative and convalescent sample unavailable for paired serology. 16 (18 %) PCR negative and serology positive in acute sample, indicative of past infection.		
Total	157 (100%)			

^a If the ratio of the convalescent/acute OD was ≥ 2 and ratio < 2 but IgM-positive (OD ≥ 0.300) in serum collected after 5 days PSO.

^b Acute and convalescent specimen were obtained from 132 of the 157 subjects enrolled in the study.

- 1 Table 2. Correlation between epidemiological characteristics and SARS-CoV-2 infections in
- 2 outpatients from Leon, Nicaragua. June-October 2020. N=157.

Pasiana amamia wagiat la	Total	acute COVID-19	Non-COVID-19	!	Odd- D-41- (050/ 61)
Socioeconomic variables	N=157	n=60 (%)	n=97 (%)	p – value	Odds Ratio (95% CI)
Age group (years)	07 (00 0)	4.4 (00.0)	00 (00 7)		,
≤40	37 (23.6)	14 (23.3)	23 (23.7)	0.040	ref
41-60	49 (31.2)	24 (40.0)	25 (25.8)	0.048	2.14 (1.007-4.539)
≥61	71 (45.2)	22 (36.7)	49 (50.5)	0.474	1.36 (0.589-3.119)
Gender	62 (20 5)	27 (45 0)	0E (0C 1)		rof
Female Male	62 (39.5) 95 (60.5)	27 (45.0)	35 (36.1)	0.260	ref
	95 (60.5)	33 (55.0)	62 (63.9)	0.268	1.45 (0.752-2.793)
Area of origin	10 (6.4)	2 (2 2)	0 (0 0)		ref
Rural Urban	10 (6.4)	2 (3.3)	8 (8.2)	0.236	
Work environment	147 (93.6)	58 (96.7)	89 (91.8)	0.236	2.61 (0.535-12.711)
Indoor	33 (21.2)	46 (76.7)	77 (80.2)		ref
Outdoor	, ,	. ,	` ,	0.599	0.811 (0.371-1.770)
Marital status	123 (78.8)	14 (23.3)	19 (19.8)	0.599	0.811 (0.371-1.770)
Single, Divorced and Widowed	64 (40.8)	24 (40.0)	40 (41.2)		ref
Partner and/or Married	93 (59.2)	36 (60.0)	57 (58.8)	0.878	1.05 (0.546-2.028)
Histo-Blood Group Antigens phenotyp	· ,	30 (00.0)	37 (36.6)	0.676	1.03 (0.340-2.020)
Blood group					
O	94 (59.9)	36 (60.0)	58 (59.8)		ref
A	46 (29.3)	18 (30.0)	28 (28.9)	0.924	1.04 (0.502-2.135)
В	12 (7.6)	5 (8.3)	7 (7.2)	0.822	1.15 (0.340-3.901)
AB	5 (3.2)	1 (1.7)	4 (4.1)	0.424	0.403 (0.043-3,747)
Lewis phenotype					
Lewis B	105 (66.9)	43 (71.7)	62 (63.9)		ref
Lewis A	12 (7.6)	2 (3.3)	10 (10.3)	0.120	0.29 (0.060-1.382)
Lewis-negative	40 (25.5)	15 (25.0)	25 (25.8)	0.705	0.87 (0.409-1.830)
Secretor phenotype	120 (07.0)	EC (02.2)	00 (04 5)		rof
Secretor Non-secretor	138 (87.9) 19 (12.1)	56 (93.3) 4 (6.7)	82 (84.5) 15 (15.5)	0.110	ref 0.39 (0.123-1.238)
Risk factors	19 (12.1)	4 (0.7)	13 (13.3)	0.110	0.59 (0.125-1.256)
	04 (54.0)	04 (50.7)	47 (40.5)	0.040	4.00 (0.700.0.050)
Chronic disease	81 (51.6)	34 (56.7)	47 (48.5)	0.318	1.39 (0.728-2.658)
Drink alcohol Smoke	55 (35.0)	20 (33.3)	35 (36.1)	0.726	0.89 (0.450-1.745)
	18 (11.5)	5 (8.3)	13 (13.4)	0.337	0.59 (0.198-1.740)
Mask wearing	107 (69 2)	43 (71.7)	64 (66 0)		ref
Always Sometimes/never	107 (68.2)	, ,	64 (66.0)	0.458	0.77 (0.380-1.546)
Social distancing	50 (31.8)	17 (28.3)	33 (34.0)		,
Travel within the country	112 (71.3)	46 (76.7)	66 (68.0)	0.247	1.54 (0.740-3.218)
Contact with a subject with RS ^a	39 (24.8) 91 (59.1)	13 (21.7) 31 (52.5)	26 (26.8) 60 (63.2)	0.470 0.194	0.76 (0.353-1.617) 0.65 (0.334-1.249)
Health worker	35 (22.3)	12 (20.0)	23 (23.7)	0.194	0.80 (0.366-1.767)
Frequency of hand washing per day	35 (22.5)	12 (20.0)	23 (23.1)	0.566	0.80 (0.300-1.707)
≥11	52 (33.3)	14 (23.3)	38 (39.6)		ref
6-10	61 (39.1)	24 (40.0)	37 (38.5)	0.166	1.76 (0.791-3.917)
0-5	43 (27.6)	22 (36.7)	21 (21.9)	0.100 0.017	2.84 (1.208-6.694)
Contact with animals	45 (21.0)	22 (30.1)	۷۱ (۲۱.۵)	0.017	2.07 (1.200-0.03 4)
Pets	119 (76.3)	52 (86.7)	67 (69.8)	0.019	2.81 (1.188-6.665)
Farm animals.	17 (10.9)	4 (6.7)	13 (113.5)	0.189	0.46 (0.141-1.471)
Others ^b	6 (3.8)	4 (6.7) 1 (1.7)	5 (5.2)	0.189	0.31 (0.035-2.707)
Any	125 (79.6)	53 (88.3)	72 (74.2)	0.289 0.037	2.63 (1.058-6.532)
Visit to Doctor	101 (64.3)	44 (73.3)	57 (58.8)	0.066	1.93 (0.958-3.888)
Treatment	142 (91.0)	56 (93.3)	86 (89.6)	0.429	1.63 (0.487-5.445)
Previous diagnosis of Covid-19	7 (4.5)	3 (5.0)	4 (4.1)	0.796	1.22 (0.264-5.667)
	()	= (0.0)	,		()

Oxygen Therapy	3 (2.3)	2 (4.7)	1 (1.1)	0.248	4.19 (0.369-47.525)
solation practice	64 (41.0)	31 (51.7)	33 (34.4)	0.034	2.04 (1.056-3.943)
Respiratory symptoms persistence					
Recovered without complications.	6 (3.8)	1 (1.7)	5 (5.2)		ref
Symptoms persist.	148 (94.9)	57 (96.6)	91 (93.8)	0.298	3.17 (0.361-27.804)
Death	2 (1.3)	1 (1.7)	1 (1.0)	0.783	1.48 (0.091-24.198)

¹ 2

^aRS stands for respiratory symptoms. ^b Includes hamster, turtles, rabbits, and/or fish.

1 Table 3. Clinical profile of SARS-CoV-2 infections in outpatients from Leon, Nicaragua. June-October 2 2020. N=157.

Clinical Manifestations	2020. N=137.					
Fever Cos of taste	Clinical Manifestations				•	
Loss of taste	Fever ^a	95 (60.9)		47 (49.0)	<0.001	4.17 (1.973-8.815)
Loss of smell	Loss of taste				0.012	
Loss of appetite 62 (39.5) 30 (50.0) 32 (33.0) 0.029 2.11 (1,082-4.11- Productive cough 64 (29.3) 22 (36.7) 24 (24.7) 0.113 0.156 (0.75-3.86) 0.868 0.94 (0.492-1.806) 0.868 0.94 (0.492-1.806) 0.868 0.94 (0.492-1.806) 0.868 0.868 0.94 (0.492-1.806) 0.869 0.87 (0.488-1.806) 0.87 (0.488-1.806) 0.87 (0.488-1.806) 0.87 (0.488-1.806) 0.87 (0.488-1.806) 0.87 (0.488-1.806) 0.87 (0.488-1.806) 0.87 (0.488-1.806) 0.87 (0.488-1.806) 0.87 (0.488-1.806) 0.87 (0.488-1.806) 0.88 (0.486-1.806) 0.87 (0.488-1.806) 0.87 (0.488-1.806) 0.88 (0.486-1.806) 0.88 (0.486-1.806) 0.87 (0.488-1.806) 0.88 (0.486-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.88 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.488 (0.488-1.806) 0.4						
Productive cough		, ,				-
Chills 69 (44.2) 26 (43.3) 43 (44.8) 0.858 0.94 (0.4924.866) Deal (10.3) 17 (17.7) 0.470 0.72 (0.288-1.777) Ear pain 34 (21.7) 12 (20.0) 22 (22.7) 0.692 0.85 (0.386-1.880) RNhorrhea 82 (52.2) 30 (50.0) 52 (63.6) 0.660 0.87 (0.454-1.649) Dry cough 107 42 (70.0) 65 (67.0) 0.690 1.15 (0.573-2.303) Bloody cough 5 (3.2) 3 (5.0) 2 (2.1) 0.324 2.50 (0.405-15.49) Sore throat 102 37 (61.7) 66 (67.0) 0.496 0.79 (0.405-15.49) Sore throat 102 37 (61.7) 66 (67.0) 0.496 0.79 (0.405-15.49) Sore throat 102 37 (61.7) 66 (67.0) 0.496 0.79 (0.405-15.41) Sore throat 102 37 (61.7) 66 (67.0) 0.496 0.79 (0.405-15.41) Sore throat 102 37 (61.7) 66 (67.0) 0.496 0.79 (0.405-15.41) Sore throat 102 47 (82.9) 10 (61.7) 46 (67.0) 0.496 0.79 (0.405-15.41) Sore throat 102 48 (48.2) 43 (3						-
Deafiness		, ,	, ,	, ,		` '
Ear pain	Chills	69 (44.2)	26 (43.3)	43 (44.8)	0.858	0.94 (0.492-1.806)
Ear pain	Deafness	25 (16.0)	8 (13.3)	17 (17.7)	0.470	0.72 (0.288-1.777)
Rhinorrhea 82 (52.2) 30 (50.0) 52 (53.6) 0.666 0.87 (0.454-1.649) Dry cough 107 42 (70.0) 65 (67.0) 0.696 1.15 (0.573-2.303) (68.2)	Ear pain					
Dry cough		\ /	` '	, ,		` ,
(68.2)			` '			
Bloody cough	Dry Cough		42 (10.0)	03 (07.0)	0.030	1.13 (0.575-2.505)
Sore throat	5		0 (5.0)	0 (0 1)		0.50 (0.405.45.445)
Shortness of breath						,
Shortness of breath	Sore throat		37 (61.7)	65 (67.0)	0.496	0.79 (0.405-1.549)
Shortness of breath		(65.0)				
Nausea	Shortness of breath		17 (28.3)	30 (30.9)	0.730	0.88 (0.435-1.792)
Vomiting 16 (10.2) 4 (6.7) 12 (12.4) 0.258 0.51 (0.155-16.48) Diarrhea 57 (36.3) 24 (40.0) 33 (34.0) 0.449 1.29 (0.664.2.516) Chest pain 53 (33.8) 19 (31.7) 34 (35.1) 0.663 0.86 (0.433-1.704) Back pain 88 (56.1) 34 (56.7) 54 (55.7) 0.903 1.04 (0.544-1.993) Muscle aches 76 (48.4) 31 (51.7) 45 (46.4) 0.521 1.24 (0.648-2.354) Joint pain 75 (49.0) 30 (51.7) 45 (47.4) 0.601 1.19 (0.619-2.289) Abdominal pain 40 (25.5) 11 (18.3) 29 (29.9) 0.151 0.56 (0.254-1.235) Dysuria 14 (8.9) 6 (10.0) 8 (8.2) 0.689 1.26 (0.412-3.818) Headache (88.8) (68.8) (68.8) (68.8) (68.8) (68.8) (68.8) (68.8) (68.8) (68.8) (68.8) (68.8) (68.8) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24) (69.254 1.24						,
Diarrhea 57 (36.3) 24 (40.0) 33 (34.0) 0.449 1.29 (0.664-2.516) Chest pain 53 (33.8) 19 (31.7) 34 (35.1) 0.663 0.86 (0.433-1.704) Back pain 88 (56.1) 34 (56.7) 54 (55.7) 0.903 1.04 (0.544-1.993) Muscle aches 76 (48.4) 31 (51.7) 45 (46.4) 0.521 1.24 (0.648-2.354) Joint pain 75 (49.0) 30 (51.7) 45 (47.4) 0.601 1.19 (0.619-2.289) Abdominal pain 40 (25.5) 11 (18.3) 29 (29.9) 0.151 0.56 (0.254-1.235) Dysuria 14 (8.9) 6 (10.0) 8 (82.2) 0.699 1.26 (0.412-3.818) Headache 108 43 (71.7) 65 (67.0) 0.574 1.23 (0.604-2.866) (68.8) Retro-orbital pain 68 (43.3) 24 (40.0) 44 (45.4) 0.670 1.17 (0.570-2.397) Fatigue 89 (56.7) 36 (60.0) 53 (54.6) 0.732 1.12 (0.580-2.174) Difficulty breathing 20 (12.7) 9 (15.0) 111 (11.3) 0.485 1.40 (0.543-3.622) Rash 11 (7.0) 4 (6.7) 7 (7.2) 0.913 0.93 (0.260-3.302) Tachycardia 41 (26.1) 18 (30.0) 23 (23.7) 0.539 1.26 (0.599-2.669) Comorbidities Number of chronic diseases 0 76 (48.4) 26 (43.3) 50 (51.5) ref 1 45 (28.87) 17 (28.3) 28 (28.9) 0.188 1.72 (0.567-3.866) 2-5 36 (22.9) 17 (28.3) 19 (19.6) 0.692 1.17 (0.542-2.51: Diabetes 20 (12.7) 11 (18.3) 9 (9.3) 0.104 2.20 (0.851-5.66) Cardiovascular disease 4 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94 Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.310-26.51 Renal disease 11 (7.0) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75 Neurological disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Cher disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.5967-0.01 Cher disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.5967-0.01 Cher disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.5967-0.01 Cher disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.5967-0.01 Cher disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Cher disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Cher disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Cher disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Cher disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Cher disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Cher disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.						
Chest pain 53 (33.8) 19 (31.7) 34 (35.1) 0.663 0.86 (0.433.1.704) 8ack pain 88 (56.1) 34 (56.7) 54 (55.7) 0.903 1.04 (0.544-1.993) Muscle aches 76 (48.4) 31 (51.7) 45 (46.4) 0.521 1.24 (0.648-2.354) Joint pain 75 (49.0) 30 (51.7) 45 (47.4) 0.601 1.19 (0.619-2.289) Abdominal pain 40 (25.5) 11 (18.3) 29 (29.9) 0.151 0.56 (0.254-1.235) Dysuria 14 (8.9) 6 (10.0) 8 (8.2) 0.689 1.26 (0.412-3.818) Headache (88.8) (68.8)		, ,				. ,
Back pain 88 (56.1) 34 (56.7) 54 (55.7) 0.903 1.04 (0.544-1.993) Muscle aches 76 (48.4) 31 (51.7) 45 (46.4) 0.521 1.24 (0.648-2.354) Joint pain 75 (49.0) 30 (51.7) 45 (47.4) 0.601 1.19 (0.619-2.289) Abdominal pain 40 (25.5) 11 (18.3) 29 (29.9) 0.151 0.56 (0.254-1.235) Dysuria 14 (8.9) 6 (10.0) 8 (8.2) 0.689 1.22 (0.604-2.486) Retro-orbital pain 68 (43.3) 24 (40.0) 44 (45.4) 0.670 1.17 (0.570-2.397) Fatigue 89 (56.7) 36 (60.0) 53 (54.6) 0.732 1.12 (0.580-2.174) Difficulty breathing 20 (12.7) 9 (15.0) 11 (11.3) 0.485 1.40 (0.543-3.62) Rash 11 (7.0) 4 (6.7) 7 (7.2) 0.913 0.93 (0.260-3.30) Tachycardia 41 (26.1) 18 (30.0) 23 (23.7) 0.539 1.26 (0.599-2.669) Comorbidities Number of chronic diseases 0 76 (48.4) 26 (43.3) 50 (5			, ,			` ,
Muscle aches 76 (48.4) 31 (51.7) 45 (46.4) 0.521 1.24 (0.648-2.354) Joint pain 75 (49.0) 30 (51.7) 45 (47.4) 0.601 1.19 (0.619-2.289) Abdominal pain 40 (25.5) 11 (18.3) 29 (29.9) 0.151 0.56 (0.254-1.235) Dysuria 14 (8.9) 6 (10.0) 8 (8.2) 0.689 1.26 (0.412-3.818) Headache 108 43 (71.7) 65 (67.0) 0.574 1.23 (0.604-2.486) (68.8) Retro-orbital pain 68 (43.3) 24 (40.0) 44 (45.4) 0.670 1.17 (0.570-2.397) Fatigue 89 (56.7) 36 (60.0) 53 (54.6) 0.732 1.12 (0.580-2.174) Difficulty breathing 20 (12.7) 9 (15.0) 11 (11.3) 0.485 1.40 (0.543-3.622) Rash 11 (7.0) 4 (6.7) 7 (7.2) 0.913 0.93 (0.260-3.330) Tachycardia 41 (26.1) 18 (30.0) 23 (23.7) 0.539 1.26 (0.599-2.669) Comorbidities Number of chronic diseases 0 76 (48.4) 26 (43.3) 50 (51.5) ref 1 45 (28.7) 17 (28.3) 28 (28.9) 0.188 1.72 (0.767-3.86) 2-5 36 (22.9) 17 (28.3) 19 (19.6) 0.692 1.17 (0.542-2.51: Diabetes 20 (12.7) 11 (18.3) 9 (9.3) 0.104 2.20 (0.851-5.66: Cardiovascular disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75: Neurological disease 4 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94 Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.837-3.16 Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Autoimmune disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Otter P 20 (12.7) 8 (13.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0						
Joint pain 75 (49.0) 30 (51.7) 45 (47.4) 0.601 1.19 (0.619-2.289) Abdominal pain 40 (25.5) 11 (18.3) 29 (29.9) 0.151 0.56 (0.254-1.235) Dysuria 14 (8.9) 6 (10.0) 8 (8.2) 0.689 1.26 (0.412-3.818) Headache 108 43 (71.7) 65 (67.0) 0.574 1.23 (0.604-2.486) (68.8) (68.8) (68.8) (68.8) (68.8) (68.8) (68.8) (68.8) (68.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8) (69.8)						
Abdominal pain	Muscle aches	76 (48.4)				1.24 (0.648-2.354)
Abdominal pain	Joint pain	75 (49.0)	30 (51.7)	45 (47.4)	0.601	1.19 (0.619-2.289)
Dysuria	Abdominal pain				0.151	0.56 (0.254-1.235)
Headache	<u>-</u>	, ,				,
Retro-orbital pain 68 (43.3) 24 (40.0) 44 (45.4) 0.670 1.17 (0.570-2.397)						
Retro-orbital pain 68 (43.3) 24 (40.0) 44 (45.4) 0.670 1.17 (0.570-2.397) Fatigue 89 (56.7) 36 (60.0) 53 (54.6) 0.732 1.12 (0.580-2.174) Difficulty breathing 20 (12.7) 9 (15.0) 11 (11.3) 0.485 1.40 (0.543-3.622) Rash 11 (7.0) 4 (6.7) 7 (7.2) 0.913 0.93 (0.260-3.330) Tachycardia 41 (26.1) 18 (30.0) 23 (23.7) 0.539 1.26 (0.599-2.669) Comorbidities Number of chronic diseases 0 76 (48.4) 26 (43.3) 50 (51.5) ref 1 45 (28.7) 17 (28.3) 28 (28.9) 0.188 1.72 (0.767-3.861 2.5 36 (22.9) 17 (28.3) 19 (19.6) 0.692 1.17 (0.542-2.51: Diabetes 20 (12.7) 11 (18.3) 9 (9.3) 0.104 2.20 (0.851-5.66: Cardiovascular disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75: 66: Cardiovascular disease 4 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94 Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.837-3.16 Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Quiter disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.596-7.01: Autoimmune disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Quiter disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Quiter disease 2 (1.3) 3 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Quiter disease 2 (1.3) 3 (1.0.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Quiter disease 2 (1.3) 3 (1.0.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Quiter disease 2 (1.3) 3 (1.7.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Quiter disease 2 (1.3) 3 (1.7.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Quiter disease 3 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0) 2.0 (1.0.0)	Ticadactic		-1 3 (11.1)	03 (07.0)	0.57 4	1.23 (0.004-2.400)
Fatigue 89 (56.7) 36 (60.0) 53 (54.6) 0.732 1.12 (0.580-2.174) Difficulty breathing 20 (12.7) 9 (15.0) 11 (11.3) 0.485 1.40 (0.543-3.622) Rash 11 (7.0) 4 (6.7) 7 (7.2) 0.913 0.93 (0.260-3.330) Comorbidities Number of chronic diseases 0 76 (48.4) 26 (43.3) 50 (51.5) ref 1 45 (28.7) 17 (28.3) 28 (28.9) 0.188 1.72 (0.767-3.86) 2-5 36 (22.9) 17 (28.3) 19 (19.6) 0.692 1.17 (0.542-2.51) Diabetes 20 (12.7) 11 (18.3) 9 (9.3) 0.104 2.20 (0.851-5.66) Cardiovascular disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75) Neurological disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75) Neurological disease 14 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94) Hypertension 57 (36.3) 26 (43.3)	Datus subital main		04 (40 0)	44 (45 4)	0.070	4 47 (0 570 0 007)
Difficulty breathing 20 (12.7) 9 (15.0) 11 (11.3) 0.485 1.40 (0.543-3.622) Rash 11 (7.0) 4 (6.7) 7 (7.2) 0.913 0.93 (0.260-3.330) Tachycardia 41 (26.1) 18 (30.0) 23 (23.7) 0.539 1.26 (0.599-2.669) Comorbidities Number of chronic diseases 0 76 (48.4) 26 (43.3) 50 (51.5) ref 1 45 (28.7) 17 (28.3) 28 (28.9) 0.188 1.72 (0.767-3.86 2-5 36 (22.9) 17 (28.3) 19 (19.6) 0.692 1.17 (0.542-2.51: Diabetes 20 (12.7) 11 (18.3) 9 (9.3) 0.104 2.20 (0.851-5.66: Cardiovascular disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75: Neurological disease 4 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94 Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.100-26.51 Liver disease 2 (1.3) 1 (1.7)<						
Rash 11 (7.0) 4 (6.7) 7 (7.2) 0.913 0.93 (0.260-3.330) Tachycardia 41 (26.1) 18 (30.0) 23 (23.7) 0.539 1.26 (0.599-2.669) Comorbidities Number of chronic diseases 0 76 (48.4) 26 (43.3) 50 (51.5) ref 1 45 (28.7) 17 (28.3) 28 (28.9) 0.188 1.72 (0.767-3.86 2-5 36 (22.9) 17 (28.3) 19 (19.6) 0.692 1.17 (0.542-2.51: Diabetes 20 (12.7) 11 (18.3) 9 (9.3) 0.104 2.20 (0.851-5.66: Cardiovascular disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75: Neurological disease 4 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94 Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.100-26.51 Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Renal disease 11 (7.0) 6 (10.0) 5 (5.2)		89 (56.7)		53 (54.6)		1.12 (0.580-2.174)
Tachycardia 41 (26.1) 18 (30.0) 23 (23.7) 0.539 1.26 (0.599-2.669) Comorbidities Number of chronic diseases 0 76 (48.4) 26 (43.3) 50 (51.5) ref 1 45 (28.7) 17 (28.3) 28 (28.9) 0.188 1.72 (0.767-3.861) 2-5 36 (22.9) 17 (28.3) 19 (19.6) 0.692 1.17 (0.542-2.51) Diabetes 20 (12.7) 11 (18.3) 9 (9.3) 0.104 2.20 (0.851-5.66) Cardiovascular disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75) Neurological disease 4 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94) Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.100-26.51) Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51) Renal disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.596-7.01) Other ^b 20 (12.7) 8 (13.3)	Difficulty breathing	20 (12.7)	9 (15.0)	11 (11.3)	0.485	1.40 (0.543-3.622)
Tachycardia 41 (26.1) 18 (30.0) 23 (23.7) 0.539 1.26 (0.599-2.669) Comorbidities Number of chronic diseases 76 (48.4) 26 (43.3) 50 (51.5) ref 1 45 (28.7) 17 (28.3) 28 (28.9) 0.188 1.72 (0.767-3.86) 2-5 36 (22.9) 17 (28.3) 19 (19.6) 0.692 1.17 (0.542-2.51) Diabetes 20 (12.7) 11 (18.3) 9 (9.3) 0.104 2.20 (0.851-5.66) Cardiovascular disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75) Neurological disease 4 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94) Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.837-3.16) Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Renal disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.596-7.01) Autoimmune disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732	Rash	11 (7.0)	4 (6.7)	7 (7.2)	0.913	0.93 (0.260-3.330)
Comorbidities Number of chronic diseases 0	Tachycardia					
Number of chronic diseases						,
0 76 (48.4) 26 (43.3) 50 (51.5) ref 1 45 (28.7) 17 (28.3) 28 (28.9) 0.188 1.72 (0.767-3.861 2-5 36 (22.9) 17 (28.3) 19 (19.6) 0.692 1.17 (0.542-2.51) Diabetes 20 (12.7) 11 (18.3) 9 (9.3) 0.104 2.20 (0.851-5.66) Cardiovascular disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75) Neurological disease 4 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94) Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.837-3.16) Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51) Autoimmune disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.596-7.01) Autoimmune disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51) Other ^b 20 (12.7) 8 (13.3) 12 (12.4) 0.861 1.09 (0.418-2.84) Vital sings ^c Mean (±SD) p - value Temperature (n=154) 37.0 (0.702) 36.9 (0.548) 0.241 Systole (mmHg) 126.9 (16.424) 122.7 (13.643) 0.105 Diastole (mmHg) 78.6 (12.036) 78.0 (10.323) 0.768 O2 Saturation (n=145) 97.0 (5.009) 98.2 (1.273) 0.024 ^a Respiratory rate (n=145) 97.0 (5.009) 98.2 (1.273) 0.024 ^a Respiratory rate (n=145) 22.2 (6.001) 22.0 (28.178) 0.972 *Reported by the patient. **This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia **n=155* d**SD, stands for standard deviation*						
1 45 (28.7) 17 (28.3) 28 (28.9) 0.188 1.72 (0.767-3.86) 2-5 36 (22.9) 17 (28.3) 19 (19.6) 0.692 1.17 (0.542-2.51: Diabetes 20 (12.7) 11 (18.3) 9 (9.3) 0.104 2.20 (0.851-5.66: Cardiovascular disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75: Neurological disease 4 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94 Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.837-3.16: Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Renal disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.596-7.01: Autoimmune disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 Other Diabete 2 (1.3) 1 (1.7) 1 (1.0) 0.732		76 (48 4)	26 (43 3)	50 (51 5)		ref
2-5					0.400	
Diabetes 20 (12.7) 11 (18.3) 9 (9.3) 0.104 2.20 (0.851-5.66) Cardiovascular disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75) Neurological disease 4 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94) Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.837-3.16) Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51) Renal disease 21 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.596-7.01) Autoimmune disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51) Other ^b 20 (12.7) 8 (13.3) 12 (12.4) 0.861 1.09 (0.418-2.84) Vital sings ^c Mean (±SD) Mean (±SD) p - value Temperature (n=154) 37.0 (0.702) 36.9 (0.548) 0.241 Systole (mmHg) 126.9 (16.424) 122.7 (13.643) 0.105 Diastole (mmHg) 78.6 (12.036) 78.0 (10.323) 0.768						
Cardiovascular disease 14 (8.9) 6 (10.0) 8 (8.2) 0.708 1.24 (0.407-3.75) Neurological disease 4 (2.5) 2 (3.3) 2 (2.1) 0.626 1.64 (0.225-11.94) Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.837-3.16) Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51) Renal disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.596-7.01) Autoimmune disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51) Other ^b 20 (12.7) 8 (13.3) 12 (12.4) 0.861 1.09 (0.418-2.84) Vital sings ^c Mean (±SD) Mean (±SD) p - value Temperature (n=154) 37.0 (0.702) 36.9 (0.548) 0.241 Systole (mmHg) 126.9 (16.424) 122.7 (13.643) 0.105 Diastole (mmHg) 78.6 (12.036) 78.0 (10.323) 0.768 O2 Saturation (n=145) 97.0 (5.009) 98.2 (1.273) 0.024* Respiratory rate (
Neurological disease						2.20 (0.851-5.663)
Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.837-3.16) Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51) Renal disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.596-7.01) Autoimmune disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51) Other ^b 20 (12.7) 8 (13.3) 12 (12.4) 0.861 1.09 (0.418-2.84) Vital sings ^c Mean (±SD) ^d Mean (±SD) p - value Temperature (n=154) 37.0 (0.702) 36.9 (0.548) 0.241 Systole (mmHg) 126.9 (16.424) 122.7 (13.643) 0.105 Diastole (mmHg) 78.6 (12.036) 78.0 (10.323) 0.768 O2 Saturation (n=145) 97.0 (5.009) 98.2 (1.273) 0.024 ^e Respiratory rate (n=145) 22.2 (6.001) 22.0 (28.178) 0.972 Heart rate 85.9 (19.106) 86.8 (13.778) 0.720 ^a Reported by the patient. b This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Id	Cardiovascular disease	14 (8.9)	6 (10.0)	8 (8.2)	0.708	1.24 (0.407-3.755)
Hypertension 57 (36.3) 26 (43.3) 31 (32.0) 0.151 1.63 (0.837-3.16) Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51) Renal disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.596-7.019) Autoimmune disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51) Other 20 (12.7) 8 (13.3) 12 (12.4) 0.861 1.09 (0.418-2.84) Vital sings 2 Mean (±SD) p - value 2 (1.24) 0.861 1.09 (0.418-2.84) Temperature (n=154) 37.0 (0.702) 36.9 (0.548) 0.241 Systole (mmHg) 126.9 (16.424) 122.7 (13.643) 0.105 Diastole (mmHg) 78.6 (12.036) 78.0 (10.323) 0.768 O2 Saturation (n=145) 97.0 (5.009) 98.2 (1.273) 0.024 Part rate 85.9 (19.106) 86.8 (13.778) 0.720 Part rate 95.9 (19.106) 86.8 (13.778) 9.7	Neurological disease	4 (2.5)	2 (3.3)	2 (2.1)	0.626	1.64 (0.225-11.946
Liver disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.1						1.63 (0.837-3.167)
Renal disease 11 (7.0) 6 (10.0) 5 (5.2) 0.256 2.04 (0.596-7.019 Autoimmune disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 0.100 0.55 0.100 0.55 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.						
Autoimmune disease 2 (1.3) 1 (1.7) 1 (1.0) 0.732 1.63 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.100-26.51 (0.1000-26.51 (0.100-26.51 (0.100-26.5						
Other ^b 20 (12.7) 8 (13.3) 12 (12.4) 0.861 1.09 (0.418-2.84) Vital sings ^c Mean (±SD) ^d Mean (±SD) p - value Temperature (n=154) 37.0 (0.702) 36.9 (0.548) 0.241 Systole (mmHg) 126.9 (16.424) 122.7 (13.643) 0.105 Diastole (mmHg) 78.6 (12.036) 78.0 (10.323) 0.768 O2 Saturation (n=145) 97.0 (5.009) 98.2 (1.273) 0.024 ^e Respiratory rate (n=145) 22.2 (6.001) 22.0 (28.178) 0.972 Heart rate 85.9 (19.106) 86.8 (13.778) 0.720 ^a Reported by the patient. b This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia ^c n=155 d SD, stands for standard deviation						
Vital sings ^c Mean (±SD) ^d Mean (±SD) p - value Temperature (n=154) 37.0 (0.702) 36.9 (0.548) 0.241 Systole (mmHg) 126.9 (16.424) 122.7 (13.643) 0.105 Diastole (mmHg) 78.6 (12.036) 78.0 (10.323) 0.768 O2 Saturation (n=145) 97.0 (5.009) 98.2 (1.273) 0.024 ^e Respiratory rate (n=145) 22.2 (6.001) 22.0 (28.178) 0.972 Heart rate 85.9 (19.106) 86.8 (13.778) 0.720 ^a Reported by the patient. ^b This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia ^c n=155 SD, stands for standard deviation						
Temperature (n=154) 37.0 (0.702) 36.9 (0.548) 0.241 Systole (mmHg) 126.9 (16.424) 122.7 (13.643) 0.105 Diastole (mmHg) 78.6 (12.036) 78.0 (10.323) 0.768 O2 Saturation (n=145) 97.0 (5.009) 98.2 (1.273) 0.024e Respiratory rate (n=145) 22.2 (6.001) 22.0 (28.178) 0.972 Heart rate 85.9 (19.106) 86.8 (13.778) 0.720 ^a Reported by the patient. b This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia ^c n=155 d SD, stands for standard deviation		20 (12.7)			0.001	· · · · · · · · · · · · · · · · · · ·
Systole (mmHg) 126.9 (16.424) 122.7 (13.643) 0.105 Diastole (mmHg) 78.6 (12.036) 78.0 (10.323) 0.768 O2 Saturation (n=145) 97.0 (5.009) 98.2 (1.273) 0.024e Respiratory rate (n=145) 22.2 (6.001) 22.0 (28.178) 0.972 Heart rate 85.9 (19.106) 86.8 (13.778) 0.720 ^a Reported by the patient. b This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia c n=155 d SD, stands for standard deviation SD, stands for standard deviation						•
Diastole (mmHg) 78.6 (12.036) 78.0 (10.323) 0.768 O2 Saturation (n=145) 97.0 (5.009) 98.2 (1.273) 0.024e Respiratory rate (n=145) 22.2 (6.001) 22.0 (28.178) 0.972 Heart rate 85.9 (19.106) 86.8 (13.778) 0.720 a Reported by the patient. b This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia c n=155 d SD, stands for standard deviation						
O2 Saturation (n=145) 97.0 (5.009) 98.2 (1.273) 0.024 ^e Respiratory rate (n=145) 22.2 (6.001) 22.0 (28.178) 0.972 Heart rate 85.9 (19.106) 86.8 (13.778) 0.720 ^a Reported by the patient. ^b This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia ^c n=155 ^d SD, stands for standard deviation						
Respiratory rate (n=145) Heart rate 22.2 (6.001) 22.0 (28.178) 0.972 85.9 (19.106) 86.8 (13.778) 0.720 8Reported by the patient. This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia Cancer n=155 SD, stands for standard deviation			78.6 (12.036)	78.0 (10.323)		
Respiratory rate (n=145) Heart rate 22.2 (6.001) 22.0 (28.178) 0.972 85.9 (19.106) 86.8 (13.778) 0.720 8Reported by the patient. This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia Cancer n=155 SD, stands for standard deviation	O2 Saturation (n=145)		97.0 (5.009)	98.2 (1.273)		0.024 ^e
Heart rate 85.9 (19.106) 86.8 (13.778) 0.720 Reported by the patient. This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia n=155 SD, stands for standard deviation			, ,			0.972
 ^a Reported by the patient. ^b This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia ^c n=155 ^d SD, stands for standard deviation 	• • • • •					
 ^b This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia ^c n=155 ^d SD, stands for standard deviation 			23.3 (10.100)	55.5 (10.110)		520
Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia [°] n=155 ^d SD, stands for standard deviation	b This include Thrombosis Sinus	itis Asthma ∩o	stennorosis Fibrom	valgia Idionathic Lei	ıkonenia Ost	tenarthritis Glaucoma
° n=155 d SD, stands for standard deviation				yaigia, iuiopatilio Let	anoponia, OSI	Jauconia, Giauconia,
^d SD, stands for standard deviation	<u> </u>	ve Conns and Dy	onpiuenna			
UI (-2.352; -0.170).						
	⁻ CI (-2.352; -0.170).					

^a Reported by the patient.

^b This include Thrombosis, Sinusitis, Asthma, Osteoporosis, Fibromyalgia, Idiopathic Leukopenia, Osteoarthritis, Glaucoma, Gastritis, Allergies, Cancer, Ulcerative Colitis and Dyslipidemia

^c n=155

^d SD, stands for standard deviation

eCI (-2.352; -0.170).

- Table 4. Correlation between blood parameters and SARS-CoV-2 infection in outpatients from 1
- 2 Leon, Nicaragua, June to October 2021. (N=157)

Laboratory indicators (acute)	acute COVID-19 n=60 Mean (±SD) ^a	non-COVID-19 n=97 Mean (±SD)	p - value
White blood cell count (cells/µl)	6.4x10 ³ (2.2 x10 ³)	8.1x10 ³ (2.4 x10 ³)	0.000*
Neutrophil (%)	57.9 (11.526)	58.7 (12.369)	0.656
Immature Granulocyte (%)	0.10 (0.354)	0.00 (0)	0.006**
Eosinophil (%)	1.05 (1.661)	1.97 (2.033)	0.004***
Basophil (%)	0.43 (0.810)	0.56 (0.957)	0.389
Lymphocyte (%)	35.5 (11.158)	34.6 (11.759)	0.618
Monocyte (%)	5.0 (3.998)	4.1 (2.734)	0.084
Platelets/µl	2.1x10 ⁵ (5.5 x10 ⁴)	2.2x10 ⁵ (6.0 x10 ⁴)	0.153
Red blood cells/ul	4.5x10 ⁶ (3.9 x10 ⁶)	$4.4x10^6 (4.4 x10^6)$	0.673
Hematocrit, %	40.3 (3.565)	39.8 (3.927)	0.631
Hemoglobin (g/dl)	13.4 (1.191)	13.3 (1.304)	0.770
Prothrombin time (seconds) ^b	14.5 (2.770)	14.4 (2.489)	0.776
Partial thromboplastin time (seconds) ^b	42.3 (17.034)	45.6 (21.685)	0.490
International normalized ratio (INR) ^b	1.29 (0.316)	1.13 (0.163)	0.009****
ESR in men ^c	11.4 (7.11)	15.7 (8.89)	0.040*****
ESR in women ^d	17.0 (9.67)	15.5 (10.71)	0.500
C reactive protein (CRP) positive ^e	42 (70.0)	48 (50.0)	0.015****
CRP concentration (mg/L)			
6-23	30 (71.4)	25 (52.1)	ref
24-196	12 (28.6)	23 (47.9)	0.063
Abnormal parameters in urine ef	9 (15.3)	14 (15.4)	0.983

Laboratory indicators (convalescent)	Acute-COVID-19 n=55 Mean (±SD)	non-COVID-19 n=81 Mean (±SD)	p - value
White blood cell count	9.1x10 ³ (3.3 x10 ³)	8.6x10 ³ (2.5 x10 ³)	0.417
Neutrophil	57.0 (9.229)	57.4 (8.897)	0.819
Eosinophil	1.96 (2.160)	2.23 (2.373)	0.492
Basophil	0.45 (0.789)	0.54 (0.807)	0.525
Lymphocyte	37.0 (8.754)	37.5 (9.886)	0.760
Monocyte	3.45 (3.276)	2.70 (2.619)	0.159
Platelet count	$2.5 \times 10^5 (7.6 \times 10^4)$	$2.6x10^5 (6.5 x10^4)$	0.233
Hemoglobin, g/ml	12.7 (1.208)	13.2 (1.252)	0.013##
Red blood cell count	$4.2x10^6 (4.1 x10^5)$	$4.4x10^6$ ($4.3 x10^5$)	0.006###
Hematocrit, %	38.2 (3.621)	40.0 (4.043)	0.007****
ESR in men	17.8 (8.01)	13.8 (7.12)	0.068
ESR in women	20.5 (10.39)	18.7 (11.33)	0.440

^a SD, stands for standard deviation


^b Examined in 25 acute COVID-19 and in 46 non-COVID-19.


[°] ESR stands for Erythrocyte sedimentation rate and was examined in 27 acute COVID-19 and 34 non-COVID-19


^d Examined in 32 acute COVID-19 and 62 non-COVID-19

³ 4 5 6 7 8 9 10 ^e For this parameter the number represent frequency and percentages in parenthesis, instead of mean and SD.

^fThe presence of nitriles, while blood cells and bacteria were considered abnormal.







Epidemiological weeks 2020